NASDAQ:ITCI Intra-Cellular Therapies (ITCI) Stock Forecast, Price & News $53.77 +1.14 (+2.17%) (As of 09/22/2023 ET) Add Compare Share Share Today's Range$52.75▼$54.7350-Day Range$52.63▼$63.5252-Week Range$42.01▼$67.05Volume612,087 shsAverage Volume605,342 shsMarket Capitalization$5.16 billionP/E RatioN/ADividend YieldN/APrice Target$78.78 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Intra-Cellular Therapies MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside46.5% Upside$78.78 Price TargetShort InterestBearish2.66% of Shares Sold ShortDividend StrengthN/ASustainability-1.23Upright™ Environmental ScoreNews Sentiment0.56Based on 7 Articles This WeekInsider TradingSelling Shares$6.36 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($2.08) to ($0.83) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.38 out of 5 starsMedical Sector230th out of 965 stocksPharmaceutical Preparations Industry91st out of 456 stocks 3.5 Analyst's Opinion Consensus RatingIntra-Cellular Therapies has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 8 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $78.78, Intra-Cellular Therapies has a forecasted upside of 46.5% from its current price of $53.77.Amount of Analyst CoverageIntra-Cellular Therapies has only been the subject of 4 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted2.66% of the outstanding shares of Intra-Cellular Therapies have been sold short.Short Interest Ratio / Days to CoverIntra-Cellular Therapies has a short interest ratio ("days to cover") of 4.Change versus previous monthShort interest in Intra-Cellular Therapies has recently increased by 0.39%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldIntra-Cellular Therapies does not currently pay a dividend.Dividend GrowthIntra-Cellular Therapies does not have a long track record of dividend growth. Previous Next 4.5 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreIntra-Cellular Therapies has received a 69.69% net impact score from Upright. The largest positive contribution comes from its "Mental diseases" impact, which is mostly driven by its "Antipsychotics", "Clinical research services for mood disorders", and "Clinical research services for substance abuse disorders " products. See details.Environmental SustainabilityThe Environmental Impact score for Intra-Cellular Therapies is -1.23. Previous Next 3.1 News and Social Media Coverage News SentimentIntra-Cellular Therapies has a news sentiment score of 0.56. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Intra-Cellular Therapies this week, compared to 3 articles on an average week.Search Interest3 people have searched for ITCI on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days.MarketBeat Follows3 people have added Intra-Cellular Therapies to their MarketBeat watchlist in the last 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Intra-Cellular Therapies insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $6,359,174.00 in company stock.Percentage Held by InsidersOnly 3.40% of the stock of Intra-Cellular Therapies is held by insiders.Percentage Held by Institutions86.94% of the stock of Intra-Cellular Therapies is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Intra-Cellular Therapies are expected to grow in the coming year, from ($2.08) to ($0.83) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Intra-Cellular Therapies is -27.86, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Intra-Cellular Therapies is -27.86, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioIntra-Cellular Therapies has a P/B Ratio of 7.76. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Intra-Cellular Therapies (NASDAQ:ITCI) StockIntra-Cellular Therapies, Inc., a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States. The company offers CAPLYTA for the treatment of schizophrenia and bipolar depression in adults. It is also involved in developing Lumateperone, which is in Phase 3 clinical trial for the treatment of various depressive disorders, as well as additional neuropsychiatric indications. In addition, the company is developing Lenrispodun (ITI-214) for the treatment of Parkinson's disease, heart failure, CNS, and other disorders; ITI-1284 for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333 for substance use disorders, pain, and psychiatric comorbidities, including depression, anxiety, and sleep disorders. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York.Read More ITCI Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ITCI Stock News HeadlinesSeptember 21, 2023 | americanbankingnews.comSharon Mates Sells 55,587 Shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) StockSeptember 20, 2023 | finance.yahoo.comIntra-Cellular Therapies to Present at the 2023 Cantor Fitzgerald Global Healthcare ConferenceSeptember 24, 2023 | Stansberry Research (Ad)Experts: NVIDIA Now "Too Big to Succeed"Several of the market’s top analysts are sounding the alarm that NVIDIA’s share price may have reached its breaking point.September 20, 2023 | gurufocus.comInsider Sell: Sharon Mates Sells 100,000 Shares of Intra-Cellular Therapies IncSeptember 11, 2023 | benzinga.comIntra-Cellular Therapies Announces Presentations at Psych Congress 2023 Including Positive Results from Study 403 in Mixed FeaturesSeptember 5, 2023 | finance.yahoo.comLoss-Making Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Expected To Breakeven In The Medium-TermSeptember 5, 2023 | finance.yahoo.comIntra-Cellular Therapies to Present at the Morgan Stanley 21st Annual Global Healthcare ConferenceAugust 23, 2023 | msn.comCantor Fitzgerald Reiterates Intra-Cellular Therapies (ITCI) Overweight RecommendationSeptember 24, 2023 | Legacy Research (Ad)ATTENTION: Digital Dollar Could Send this $0.25 Play SkyrocketingIn just a few days, the U.S. government could announce this mandatory recall on the U.S. dollar… And replace it with a new digital dollar. And that could send this $0.25 alternative investment skyrocketing.August 12, 2023 | seekingalpha.comIntra-Cellular Therapies: Caplyta's Rise And A Promising PipelineAugust 4, 2023 | finance.yahoo.comIntra-Cellular Therapies Reports Second Quarter 2023 Financial Results and Raises 2023 CAPLYTA Sales GuidanceAugust 3, 2023 | seekingalpha.comIntra-Cellular Therapies Q2 2023 Earnings PreviewJuly 28, 2023 | finance.yahoo.comIntra-Cellular Therapies to Host Second Quarter 2023 Financial Results Conference Call and WebcastJuly 6, 2023 | markets.businessinsider.comNeedham Maintains Buy Rating for Intra-Cellular Therapies: Here's What You Need To KnowJune 22, 2023 | markets.businessinsider.comRBC Capital Sticks to Their Buy Rating for Intra-Cellular Therapies (ITCI)June 20, 2023 | finance.yahoo.comDrug Stock Poised For Growth With Record Sales, Strong OutlookJune 5, 2023 | finance.yahoo.comITCI Jul 2023 65.000 callJune 5, 2023 | msn.comJP Morgan Maintains Intra-Cellular Therapies (ITCI) Overweight RecommendationJune 5, 2023 | markets.businessinsider.comAnalyst Expectations for Intra-Cellular Therapies's FutureJune 5, 2023 | finance.yahoo.comIntra-Cellular Therapies to Present at the Goldman Sachs 44th Annual Global Healthcare ConferenceMay 31, 2023 | finance.yahoo.comIntra-Cellular Therapies Announces CAPLYTA Data Presentations at the American Society of Clinical Psychopharmacology Annual MeetingMay 31, 2023 | finance.yahoo.comIntra-Cellular Therapies Announces CAPLYTA Data Presentations at the American Society of Clinical Psychopharmacology Annual MeetingMay 8, 2023 | msn.comMizuho Maintains Intra-Cellular Therapies (ITCI) Buy RecommendationMay 8, 2023 | finance.yahoo.comInvesting in Intra-Cellular Therapies (NASDAQ:ITCI) three years ago would have delivered you a 208% gainMay 5, 2023 | msn.comCantor Fitzgerald Maintains Intra-Cellular Therapies (ITCI) Overweight RecommendationMay 5, 2023 | msn.comRBC Capital Maintains Intra-Cellular Therapies (ITCI) Outperform RecommendationMay 4, 2023 | finance.yahoo.com‘Don’t let the earnings beats fool you’: Morgan Stanley advises investors to temper their optimism amidst a looming recession — use these 2 stocks for protectionSee More Headlines Receive ITCI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Intra-Cellular Therapies and its competitors with MarketBeat's FREE daily newsletter. Email Address ITCI Company Calendar Last Earnings8/03/2023Today9/24/2023Next Earnings (Estimated)11/02/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ITCI CUSIPN/A CIK1567514 Webwww.intracellulartherapies.com Phone(464) 440-9333Fax646-440-9334Employees561Year FoundedN/APrice Target and Rating Average Stock Price Forecast$78.78 High Stock Price Forecast$98.00 Low Stock Price Forecast$62.00 Forecasted Upside/Downside+46.5%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage8 Analysts Profitability EPS (Most Recent Fiscal Year)($1.93) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-256,260,000.00 Net Margins-50.40% Pretax Margin-50.36% Return on Equity-28.63% Return on Assets-24.81% Debt Debt-to-Equity RatioN/A Current Ratio7.58 Quick Ratio7.13 Sales & Book Value Annual Sales$250.31 million Price / Sales20.61 Cash FlowN/A Price / Cash FlowN/A Book Value$6.93 per share Price / Book7.76Miscellaneous Outstanding Shares95,930,000Free Float92,665,000Market Cap$5.16 billion OptionableOptionable Beta1.10 10 Best Stocks to Own in 2023Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2023 and why they should be in your portfolio. Get This Free Report Key ExecutivesDr. Sharon Mates Ph.D. (Age 70)Co-Founder, Chairman, CEO & Pres Comp: $2.23MMr. Lawrence J. Hineline CPA (Age 67)CPA, Sr. VP of Fin., CFO, Treasurer & Assistant Sec. Comp: $820.53kMr. Michael I. Halstead J.D. (Age 50)Exec. VP, Gen. Counsel & Sec. Comp: $983.65kDr. Suresh K. Durgam M.D. (Age 54)Exec. VP & Chief Medical Officer Comp: $961.84kMr. Mark Neumann (Age 60)EVP & Chief Commercial Officer Comp: $998.36kDr. Robert E. Davis Ph.D. (Age 72)Sr. VP & Chief Scientific Officer Mr. Juan Fernando Sanchez (Age 52)VP of Corp. Communications & Investor Relations Ms. Karen Patruno Sheehy Esq. (Age 61)Sr. VP & Chief Compliance Officer Dr. Michael OlchaskeySr. VP & Head of Regulatory AffairsMr. John A. BardiSr. VP of Market Access, Policy & Gov. AffairsMore ExecutivesKey CompetitorsPrestige Consumer HealthcareNYSE:PBHThe Ensign GroupNASDAQ:ENSGAbcamNASDAQ:ABCMHalozyme TherapeuticsNASDAQ:HALOBellRing BrandsNYSE:BRBRView All CompetitorsInsiders & InstitutionsSharon MatesSold 55,587 sharesTotal: $2.99 M ($53.76/share)Perceptive Advisors LLCBought 245,800 shares on 8/24/2023Ownership: 0.256%Wolverine Trading LLCSold 3,600 shares on 8/23/2023Ownership: 0.000%California State Teachers Retirement SystemSold 2,338 shares on 8/21/2023Ownership: 0.111%Teachers Retirement System of The State of KentuckySold 16,923 shares on 8/21/2023Ownership: 0.006%View All Insider TransactionsView All Institutional Transactions ITCI Stock - Frequently Asked Questions Should I buy or sell Intra-Cellular Therapies stock right now? 8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Intra-Cellular Therapies in the last twelve months. There are currently 8 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ITCI shares. View ITCI analyst ratings or view top-rated stocks. What is Intra-Cellular Therapies' stock price forecast for 2023? 8 equities research analysts have issued 12 month target prices for Intra-Cellular Therapies' stock. Their ITCI share price forecasts range from $62.00 to $98.00. On average, they expect the company's stock price to reach $78.78 in the next year. This suggests a possible upside of 46.5% from the stock's current price. View analysts price targets for ITCI or view top-rated stocks among Wall Street analysts. How have ITCI shares performed in 2023? Intra-Cellular Therapies' stock was trading at $52.92 at the beginning of 2023. Since then, ITCI stock has increased by 1.6% and is now trading at $53.77. View the best growth stocks for 2023 here. When is Intra-Cellular Therapies' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, November 2nd 2023. View our ITCI earnings forecast. How were Intra-Cellular Therapies' earnings last quarter? Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) released its quarterly earnings data on Thursday, August, 3rd. The biopharmaceutical company reported ($0.45) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.62) by $0.17. The biopharmaceutical company had revenue of $110.80 million for the quarter, compared to analysts' expectations of $106.45 million. Intra-Cellular Therapies had a negative trailing twelve-month return on equity of 28.63% and a negative net margin of 50.40%. The business's revenue for the quarter was up 99.4% on a year-over-year basis. During the same quarter in the previous year, the business posted ($0.92) EPS. What ETFs hold Intra-Cellular Therapies' stock? ETFs with the largest weight of Intra-Cellular Therapies (NASDAQ:ITCI) stock in their portfolio include AdvisorShares Psychedelics ETF (PSIL), iShares Neuroscience and Healthcare ETF (IBRN), SPDR S&P Pharmaceuticals ETF (XPH), Direxion Daily Pharmaceutical & Medical Bull 3X Shares ETF (PILL), iShares U.S. Pharmaceuticals ETF (IHE), Virtus LifeSci Biotech Products ETF (BBP), Principal Healthcare Innovators ETF (BTEC) and Invesco Dorsey Wright Healthcare Momentum ETF (PTH). What other stocks do shareholders of Intra-Cellular Therapies own? Based on aggregate information from My MarketBeat watchlists, some companies that other Intra-Cellular Therapies investors own include Sorrento Therapeutics (SRNE), Amarin (AMRN), Gilead Sciences (GILD), CRISPR Therapeutics (CRSP), Synergy Pharmaceuticals (SGYP), Myovant Sciences (MYOV), Novavax (NVAX), Pfizer (PFE), AbbVie (ABBV) and Clovis Oncology (CLVS). What is Intra-Cellular Therapies' stock symbol? Intra-Cellular Therapies trades on the NASDAQ under the ticker symbol "ITCI." Who are Intra-Cellular Therapies' major shareholders? Intra-Cellular Therapies' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (7.91%), Wasatch Advisors LP (3.63%), Bellevue Group AG (3.34%), State Street Corp (2.20%), Alliancebernstein L.P. (2.13%) and JPMorgan Chase & Co. (2.06%). Insiders that own company stock include Christopher D Alafi, Christopher D Alafi, Joel S Marcus, Lawrence J Hineline, Lawrence J Hineline, Mark Neumann, Michael Halstead, Nostrand Robert L Van, Rory B Riggs, Sharon Mates and Suresh K Durgam. View institutional ownership trends. How do I buy shares of Intra-Cellular Therapies? Shares of ITCI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Intra-Cellular Therapies' stock price today? One share of ITCI stock can currently be purchased for approximately $53.77. How much money does Intra-Cellular Therapies make? Intra-Cellular Therapies (NASDAQ:ITCI) has a market capitalization of $5.16 billion and generates $250.31 million in revenue each year. The biopharmaceutical company earns $-256,260,000.00 in net income (profit) each year or ($1.93) on an earnings per share basis. How many employees does Intra-Cellular Therapies have? The company employs 561 workers across the globe. How can I contact Intra-Cellular Therapies? Intra-Cellular Therapies' mailing address is 430 EAST 29TH STREET, NEW YORK NY, 10016. The official website for the company is www.intracellulartherapies.com. The biopharmaceutical company can be reached via phone at (464) 440-9333, via email at ir@intracellulartherapies.com, or via fax at 646-440-9334. This page (NASDAQ:ITCI) was last updated on 9/24/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Intra-Cellular Therapies, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.